AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas
International Journal of Cancer, 05/31/2012
Qi W et al. – AT9283 plus docetaxel may represent a novel therapeutic strategy in B-cell NHL and warrant early phase clinical trial evaluation.
Methods- Whether or not AT9283 in combination with docetaxel was more efficient in inducing apoptosis than AT9283 or docetaxel alone was evaluated.
- At very low doses (5 nM) apoptosis was doubled in the combination (23%) compared to AT9283 or docetaxel alone (10%).
- A mouse xenograft model of mantle cell lymphoma demonstrated that AT9283 at 15 mg/kg and docetaxel (10 mg/kg) alone had modest anti-tumor activity. However, AT9283 at 20 mg/kg and AT9283 (15 or 20 mg/kg) plus docetaxel (10 mg/kg) demonstrated a statistically significant tumor growth inhibition and enhanced survival.
